Tin(II) and Tin(IV) Complexes Incorporating the Oxygen Tripodal Ligands [(η5-C5R5)Co{P(OEt)2O}3]−, (R = H, Me; Et = -C2H5) as Potent Inflammatory Mediator Inhibitors: Cytotoxic Properties and Biological Activities against the Platelet-Activating Factor (PAF) and Thrombin

Metal complexes displaying antiplatelet properties is a promising research area. In our methodology, Platelet-Activating Factor (PAF), the most potent lipid pro-inflammatory mediator, serves as a biological probe. The antiplatelet activity is exerted by the inhibition of the PAF-induced aggregation in washed rabbit platelets (WRPs) and in rabbit plasma rich in platelets (rPRPs). Herein, the synthesis and biological investigation of a series of organometallic tin(II) and tin(IV) complexes, featuring the oxygen tripodal Kläui ligands [(η5-C5R5)Co{P(OEt)2O}3]−, {R = H, (LOEt−); Me (L*OEt−)}, are reported. Reaction of NaLOEt (1a) and NaL*OEt (1b) with SnCl2, yielded the rare four-coordinate LOEtSnCl (2a) and L*OEtSnCl (2b) complexes. Accordingly, LOEtSnPh3 (3a) and L*OEtSnPh3 (3b) were prepared, starting from Ph3SnCl. Characterization includes spectroscopy and X-ray diffraction studies for 2a, 2b and 3b. The antiplatelet activity of the lead complexes 2b and 3a (IC50 = 0.5 μΜ) is superior compared to that of 1a and 1b, while both complexes display a pronounced inhibitory activity against thrombin (IC50 = 1.8 μM and 0.6 μM). The in vitro cytotoxic activities of 3a and 2b on human Jurkat T lymphoblastic tumor cell line is higher than that of cisplatin.

[1]  Xiaoting Lu,et al.  A microporous 2D cobalt-based MOF with pyridyl sites and open metal sites for selective adsorption of CO2 , 2022, Microporous and Mesoporous Materials.

[2]  Ting‐Shen Kuo,et al.  Ambiphilic Nature of Dipyrrolylpyridine-Supported Divalent Germanium and Tin Compounds , 2021, Organometallics.

[3]  B. Larijani,et al.  Recent advances in biological activities of rhodium complexes: Their applications in drug discovery research. , 2021, European journal of medicinal chemistry.

[4]  A. Philippopoulos,et al.  Antithrombotic and antiplatelet activity of an organometallic rhodium(I) complex incorporating a substituted thieno‐[2,3‐ d ]‐pyrimidine ligand: Synthesis, structural characterization, and molecular docking calculations , 2021 .

[5]  A. Page,et al.  Cytotoxicity of Tin(IV)-based compounds: A review , 2021 .

[6]  I. Rodríguez-García,et al.  The Proven Versatility of Cp2TiCl. , 2020, The Journal of organic chemistry.

[7]  A. Tsoupras,et al.  Antithrombotic properties of Spirulina extracts against platelet-activating factor and thrombin , 2020 .

[8]  U. Abram,et al.  One Ligand, One Metal, Seven Oxidation States: Stable Technetium Complexes with the "Kläui Ligand". , 2020, Inorganic chemistry.

[9]  I. Zabetakis,et al.  The Effects of Oxidation on the Antithrombotic Properties of Tea Lipids against PAF, Thrombin, Collagen, and ADP , 2020, Foods.

[10]  J. Kallitsis,et al.  Substituted pyridine-quinoline ligands as building blocks for neutral rhodium(III) complexes. Synthesis, structural characterization studies and anti-platelet activity towards the Platelet-Activating Factor (PAF) , 2020 .

[11]  I. Zabetakis,et al.  Forty Years Since the Structural Elucidation of Platelet-Activating Factor (PAF): Historical, Current, and Future Research Perspectives , 2019, Molecules.

[12]  N. Hadjiliadis,et al.  Anti-proliferative and antitumor activity of organotin(IV) compounds. An overview of the last decade and future perspectives. , 2019, Journal of inorganic biochemistry.

[13]  S. Nolan,et al.  In vitro Anti‐atherogenic Properties of N‐Heterocyclic Carbene Aurate(I) Compounds , 2018, ChemMedChem.

[14]  Alex C. Bissember,et al.  Progress in the Development of Platelet‐Activating Factor Receptor (PAFr) Antagonists and Applications in the Treatment of Inflammatory Diseases , 2018, ChemMedChem.

[15]  Xin Liu,et al.  Synthesis, characterization, and catalytic performance of Aluminum and Tin Compounds with β -diketiminato ligand , 2018, Journal of Organometallic Chemistry.

[16]  E. Yousif,et al.  A Review of Organotin Compounds: Chemistry and Applications , 2018, Archives of Organic and Inorganic Chemical Sciences.

[17]  K. Shankland,et al.  Ruthenium-conjugated chrysin analogues modulate platelet activity, thrombus formation and haemostasis with enhanced efficacy , 2017, Scientific Reports.

[18]  M. Velusamy,et al.  Antiplatelet Activity of a Newly Synthesized Novel Ruthenium (II): A Potential Role for Akt/JNK Signaling , 2017, International journal of molecular sciences.

[19]  E. Tsilibary,et al.  A Review on Platelet Activating Factor Inhibitors: Could a New Class of Potent Metal-Based Anti-Inflammatory Drugs Induce Anticancer Properties? , 2017, Bioinorganic chemistry and applications.

[20]  N. Rajab,et al.  Syntheses, characterization, X-ray diffraction studies and in vitro antitumor activities of diorganotin(IV) derivatives of bis(p-substituted-N-methylbenzylaminedithiocarbamates) , 2015 .

[21]  L. O. SnPh.  GENOTOXIC EVALUATION OF NEWLY SYNTHESIZED ORGANOMETALLIC COMPOUNDS OF TIN DAMATI , 2015 .

[22]  Yunlan Li,et al.  Medicinal properties of organotin compounds and their limitations caused by toxicity , 2014 .

[23]  S. Tabassum,et al.  Organo-tin antitumor compounds: Their present status in drug development and future perspectives , 2014 .

[24]  N. Rajab,et al.  Triorganotin(IV) complexes with o-substituted arylhydroxamates: Synthesis, spectroscopic characterization, X-ray structures and in vitro cytotoxic activities , 2014 .

[25]  H. Khavasi,et al.  Synthesis, spectroscopic characterization, structural studies and antibacterial and antitumor activities of diorganotin complexes with 3-methoxysalicylaldehyde thiosemicarbazone , 2013 .

[26]  A. Philippopoulos,et al.  Synthesis, biochemical evaluation and molecular modeling studies of novel rhodium complexes with nanomolar activity against Platelet Activating Factor. , 2013, Journal of inorganic biochemistry.

[27]  R. Chammas,et al.  Expression of PAFR as Part of a Prosurvival Response to Chemotherapy: A Novel Target for Combination Therapy in Melanoma , 2012, Mediators of inflammation.

[28]  K. Pappas,et al.  Platelet‐activating factor detection, metabolism, and inhibitors in the ethanologenic bacterium Zymomonas mobilis , 2012 .

[29]  P. Kyritsis,et al.  Inhibitory activity of the novel Zn[(OPPh2)(SePPh2)N]2 complex towards the Platelet Activating Factor (PAF) and thrombin: Comparison with its isomorphous Co(II) and Ni(II) analogues , 2011 .

[30]  G. Panayotou,et al.  Paf-Metabolic Enzymes and Paf-like Activity in L. Infantum and L. Major Promastigotes , 2011 .

[31]  M. Lazanas,et al.  In vitro anti-inflammatory and anti-coagulant effects of antibiotics towards Platelet Activating Factor and thrombin , 2011, Journal of Inflammation.

[32]  P. Stivaktakis,et al.  Differential Micronuclei Induction in Human Lymphocyte Cultures by Imidacloprid in the Presence of Potassium Nitrate , 2010, TheScientificWorldJournal.

[33]  A. Tsoupras,et al.  The implication of platelet activating factor in cancer growth and metastasis: potent beneficial role of PAF-inhibitors and antioxidants. , 2009, Infectious disorders drug targets.

[34]  Gunnar Brunborg,et al.  The comet assay: topical issues. , 2008, Mutagenesis.

[35]  T. Baul.  Antimicrobial activity of organotin(IV) compounds: a review , 2008 .

[36]  Qian-Feng Zhang,et al.  Recent developments in the coordination and organometallic chemistry of Kläui oxygen tripodal ligands , 2007 .

[37]  G. Panayotou,et al.  Isolation and identification of hydroxyl-platelet-activating factor from natural sources. , 2006, Life sciences.

[38]  A. Wilkins,et al.  Six-coordinate organotin(IV) complexes formed using the Kläui ligands; [CpCo{P(OR′)2O}3]SnR3 − nCln , 2006 .

[39]  Iwao Omae,et al.  Organotin antifouling paints and their alternatives , 2003 .

[40]  L. Ronconi,et al.  Synthesis, characterization and in vitro cytotoxicity of new organotin(IV) derivatives of N-methylglycine. , 2002, Journal of inorganic biochemistry.

[41]  A. Rheingold,et al.  Nitrogen Tripod Ligand/Oxygen Tripod Ligand Indium(III) Complexes: The First Structurally Characterized Trofimenko−Kläui Complex [η5-(C5H5)Co{P(OCH3)2(O)}3InHB(pz)3][InCl4] (pz = pyrazol-1-yl) , 2001 .

[42]  P. Power,et al.  Synthesis and Structures of Monomeric Divalent Germanium and Tin Compounds Containing a Bulky Diketiminato Ligand , 2001 .

[43]  H. V. Rasika Dias,et al.  Azido Derivatives of Germanium(II) and Tin(II): Syntheses and Characterization of [(Mes)2DAP]GeN3, [(Mes)2DAP]SnN3, and the Corresponding Chloro Analogues Featuring Heterocyclic Six-π-Electron Ring Systems (where [(Mes)2DAP] = {N(Mes)C(Me)}2CH) , 2001 .

[44]  S Russo,et al.  PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. , 2000, The American journal of pathology.

[45]  G. Kociok‐Köhn,et al.  Oxidation of germanium(II) azides with HN3: a convenient route to six-co-ordinate triazidogermanium(IV) compounds , 2000 .

[46]  K. Jurkschat,et al.  The First Rigid O,C,O-Pincer Ligand and Its Application for the Synthesis of Penta- and Hexacoordinate Organotin(IV) Compounds† , 1998 .

[47]  I. Marziano,et al.  SYNTHESIS AND CHARACTERIZATION OF SN(ETA 5-C5ME5)CL AND SNETA 5-C5ME4(SIME2BUT)CL , 1997 .

[48]  H. Heuer.  Current status of PAF antagonists , 1992, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[49]  C. Carrano,et al.  Synthesis and structure of two tris(pyrazolyl)boratotin(II) compounds , 1988 .

[50]  Marianne Cooper,et al.  Introduction and overview , 1988, J. Am. Soc. Inf. Sci..

[51]  A. Saxena.  Organotin compounds: Toxicology and biomedicinal applications , 1988 .

[52]  R. Boese,et al.  Crystal structure and coordination chemistry of the pentane-soluble sodium salt of an oxygen tripod ligand. , 1987 .

[53]  G. Navon,et al.  Novel organometallic ionophore with specificity toward lithium ion , 1986 .

[54]  Román E. Enrique,et al.  A novel access to the anionic permethylated fac-tripod ligand [C5Me5Co&P(O)(OEt)2&3]−, and its derived trinuclear and binuclear complexes , 1986 .

[55]  H. Nomura,et al.  CV-3988 - a specific antagonist of platelet activating factor (PAF). , 1983, Life sciences.

[56]  D. Hanahan,et al.  Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). , 1979, The Journal of biological chemistry.

[57]  W. Kläui.  [(C5H5)CO{P(0)(0C2H5)2}3]-: Eine einfache Synthese eines metallorganischen Tripodliganden und seine Reaktivität gegenüber den Kationen der III. Hauptgruppe / [(C5H5)CO{P(0)(0C2H5)2}3]-: A Convenient Synthesis of an Organometallic Tripod Ligand and its Reactivity towards the Main Group III Cations , 1979 .

[58]  W. Kläui,et al.  Molecular structures and solid-solid phase transitions of trinuclear CpCo[P(O)(OR)2]32M complexes , 1979 .

[59]  K. Dehnicke,et al.  Dreikernige Sandwichkomplexe mit Dialkylphosphonat‐Brückenliganden: Synthese, NMR‐, IR‐ und Raman‐spektroskopische Untersuchungen , 1978 .

[60]  A. Spek,et al.  The crystal and molecular structure of cyclopentadienyltin(II) chloride. The bonding of the cyclopentadienyl group in tin(II) compounds , 1975 .

[61]  H. Fritz.  Infrared and Raman Spectral Studies of π Complexes Formed Between Metals and CnHnRings , 1964 .